As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
Feature|Articles|November 2, 2026
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
Author(s)Alex Biese
Fact checked by: By ONN Staff
Nurses and NPs share how they manage rash, stomatitis, diarrhea, dose holds, cost, and trial eligibility with oral daraxonrasib in pancreatic cancer.
Advertisement
Advertisement
For Yolanda Justal, APRN, of the University of Miami Sylvester Comprehensive Cancer Center, the August 26, 2026, FDA approval of daraxonrasib (Rasonque) for previously treated metastatic pancreatic adenocarcinoma was the result of years of involvement in the phase 3 RASolute 302 trial (NCT06625320).1
Related to this article
Nicole Doell, MSN, RN, of Sylvester explains how nurses can address breast cancer misinformation without judgment and share vetted resources.
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
Sylvester's Nicole Doell, MSN, RN, discusses how oncology nurses can support patients with breast cancer emotionally, from diagnosis to survivorship.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Daraxonrasib, tarlatamab, an mRNA melanoma therapy and ivonescimab led ESMO 2026. Tell us which findings you can act on now.
At an Oncology Nursing News roundtable, APPs discussed earlier lifileucel referral, IL-2 dosing, and toxicities that emerge after discharge.
Advertisement
Advertisement